FDA OKs Nationwide Children’s Hospital’s IND for Sarepta’s microdystrophin gene therapy for DMD; shares up 2% – Seeking Alpha
Life Sciences Intellectual Property Review |
FDA OKs Nationwide Children's Hospital's IND for Sarepta's microdystrophin gene therapy for DMD; shares up 2%
Seeking Alpha The FDA has signed off on Nationwide Children's Hospital's IND application seeking approval to begin a Phase 1/2a study of evaluating a new gene therapy candidate, AAVrh74.MHCK7.micro-Dystrophin, in patients with Duchenne muscular dystrophy (DMD) … Sarepta Therapeutics (SRPT): FDA Clears GALGT2 Gene Therapy Program – William Blair Sarepta Therapeutics and Nationwide Children's Hospital Announce FDA Clearance of IND for Micro-Dystrophin Gene … Sarepta Therapeutics And Nationwide Children's Hospital Announce US Food And Drug Administration (FDA … |
